Imaging and therapeutic radiotracers for prostate cancer
Radiotracers that target glutamate carboxypeptidase II, also known as the prostate specific membrane antigen (GCP(II)/PSMA), have shown exceptional promise for prostate cancer imaging and molecular radiotherapy. A number of bioconjugates have been developed to target GCP(II)/PSMA which utilise the s...
Main Author: | Young, Jennifer Denise |
---|---|
Other Authors: | Blower, Philip John ; Mullen, Gregory Edgar David |
Published: |
King's College London (University of London)
2018
|
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.762404 |
Similar Items
-
Nuclear medicine in prostate cancer: A new era for radiotracers
by: Vincenzo Cuccurullo, et al.
Published: (2018-01-01) -
Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
by: Wietske I. Luining, et al.
Published: (2021-01-01) -
Imaging in hearing using radiotracers
by: Berding Georg, et al.
Published: (2017-09-01) -
Comparison of two peptide radiotracers for prostate carcinoma targeting
by: Bluma Linkowski Faintuch, et al.
Published: (2012-01-01) -
Current radiotracers to image neurodegenerative diseases
by: Solveig Tiepolt, et al.
Published: (2019-07-01)